Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Prognostic value of the IASLC/ATS/ERS classification of lung adenocarcinoma in stage I disease of Japanese cases.

Woo T, Okudela K, Mitsui H, Tajiri M, Yamamoto T, Rino Y, Ohashi K, Masuda M.

Pathol Int. 2012 Dec;62(12):785-91. doi: 10.1111/pin.12016.

PMID:
23252867
[PubMed - indexed for MEDLINE]
2.

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.

Yoshizawa A, Motoi N, Riely GJ, Sima CS, Gerald WL, Kris MG, Park BJ, Rusch VW, Travis WD.

Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.

PMID:
21252858
[PubMed - indexed for MEDLINE]
Free Article
3.

Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.

Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H, Haga H.

J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8.

PMID:
23242438
[PubMed - indexed for MEDLINE]
4.

Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma.

Gu J, Lu C, Guo J, Chen L, Chu Y, Ji Y, Ge D.

J Surg Oncol. 2013 Apr;107(5):474-80. doi: 10.1002/jso.23259. Epub 2012 Sep 5.

PMID:
22952152
[PubMed - indexed for MEDLINE]
5.

The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival.

Warth A, Muley T, Meister M, Stenzinger A, Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H, Weichert W.

J Clin Oncol. 2012 May 1;30(13):1438-46. doi: 10.1200/JCO.2011.37.2185. Epub 2012 Mar 5.

PMID:
22393100
[PubMed - indexed for MEDLINE]
6.

Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.

Song Z, Zhu H, Guo Z, Wu W, Sun W, Zhang Y.

Eur J Surg Oncol. 2013 Nov;39(11):1262-8. doi: 10.1016/j.ejso.2013.08.026. Epub 2013 Sep 11.

PMID:
24063970
[PubMed - indexed for MEDLINE]
7.

Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.

Takahashi M, Shigematsu Y, Ohta M, Tokumasu H, Matsukura T, Hirai T.

J Thorac Cardiovasc Surg. 2014 Jan;147(1):54-9. doi: 10.1016/j.jtcvs.2013.08.058. Epub 2013 Oct 13.

PMID:
24131786
[PubMed - indexed for MEDLINE]
8.

New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma.

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G.

J Thorac Oncol. 2013 May;8(5):612-8. doi: 10.1097/JTO.0b013e318287c3eb.

PMID:
23584293
[PubMed - indexed for MEDLINE]
9.

The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma.

Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady PW, Marshman D, Mathur MM, Gill AJ.

Pathology. 2013 Oct;45(6):553-8. doi: 10.1097/PAT.0b013e32836532ae.

PMID:
24018816
[PubMed - indexed for MEDLINE]
10.
11.

Why do pathological stage IA lung adenocarcinomas vary from prognosis?: a clinicopathologic study of 176 patients with pathological stage IA lung adenocarcinoma based on the IASLC/ATS/ERS classification.

Zhang J, Wu J, Tan Q, Zhu L, Gao W.

J Thorac Oncol. 2013 Sep;8(9):1196-202. doi: 10.1097/JTO.0b013e31829f09a7.

PMID:
23945388
[PubMed - indexed for MEDLINE]
12.

A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma.

Kadota K, Suzuki K, Kachala SS, Zabor EC, Sima CS, Moreira AL, Yoshizawa A, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Mod Pathol. 2012 Aug;25(8):1117-27. doi: 10.1038/modpathol.2012.58. Epub 2012 Apr 13.

PMID:
22499226
[PubMed - indexed for MEDLINE]
Free Article
13.

The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations.

Tsuta K, Kawago M, Inoue E, Yoshida A, Takahashi F, Sakurai H, Watanabe S, Takeuchi M, Furuta K, Asamura H, Tsuda H.

Lung Cancer. 2013 Sep;81(3):371-6. doi: 10.1016/j.lungcan.2013.06.012. Epub 2013 Jul 26.

PMID:
23891509
[PubMed - indexed for MEDLINE]
14.

Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease.

Kadota K, Villena-Vargas J, Yoshizawa A, Motoi N, Sima CS, Riely GJ, Rusch VW, Adusumilli PS, Travis WD.

Am J Surg Pathol. 2014 Apr;38(4):448-60. doi: 10.1097/PAS.0000000000000134.

PMID:
24472852
[PubMed - indexed for MEDLINE]
15.

[Prognostic significance of a newly proposed grading and scoring system in stage I pulmonary adenocarcinoma].

Ding FG, Liu B, Zhang XH, Xu Y, Yu B, Zhang RS, He Y, Ma HH, Lu ZF, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Mar;41(3):145-50. doi: 10.3760/cma.j.issn.0529-5807.2012.03.001. Chinese.

PMID:
22800475
[PubMed - indexed for MEDLINE]
16.

Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma.

Kadota K, Nitadori J, Sarkaria IS, Sima CS, Jia X, Yoshizawa A, Rusch VW, Travis WD, Adusumilli PS.

Cancer. 2013 Mar 1;119(5):931-8. doi: 10.1002/cncr.27863. Epub 2012 Oct 23.

PMID:
23096929
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma.

Kadota K, Colovos C, Suzuki K, Rizk NP, Dunphy MP, Zabor EC, Sima CS, Yoshizawa A, Travis WD, Rusch VW, Adusumilli PS.

Ann Surg Oncol. 2012 Oct;19(11):3598-605. doi: 10.1245/s10434-012-2414-3. Epub 2012 May 30.

PMID:
22644511
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.

Russell PA, Barnett SA, Walkiewicz M, Wainer Z, Conron M, Wright GM, Gooi J, Knight S, Wynne R, Liew D, John T.

J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

PMID:
23486266
[PubMed - indexed for MEDLINE]
19.

Cytologic subtyping of lung adenocarcinoma by using the proposed International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) adenocarcinoma classification.

Rodriguez EF, Monaco SE, Dacic S.

Cancer Cytopathol. 2013 Nov;121(11):629-37. doi: 10.1002/cncy.21314. Epub 2013 Aug 13.

PMID:
23943235
[PubMed - indexed for MEDLINE]
20.

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma.

Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, Franklin W, Gazdar A, Gould M, Hasleton P, Henderson D, Johnson B, Johnson D, Kerr K, Kuriyama K, Lee JS, Miller VA, Petersen I, Roggli V, Rosell R, Saijo N, Thunnissen E, Tsao M, Yankelewitz D.

J Thorac Oncol. 2011 Feb;6(2):244-85. doi: 10.1097/JTO.0b013e318206a221. Review.

PMID:
21252716
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk